UMN Pharma Inc.
Quick facts
Phase 3 pipeline
- approved egg-derived TIV
- ASP7374 · Immunology
ASP7374 is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses inflammatory signaling pathways involved in immune-mediated diseases.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about UMN Pharma Inc.
What is UMN Pharma Inc.'s pipeline?
UMN Pharma Inc. has 2 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include approved egg-derived TIV, ASP7374.
Related
- Sector hub: All tracked pharma companies